Profile data is unavailable for this security.
About the company
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
- Revenue in USD (TTM)1.06bn
- Net income in USD-17.69m
- Incorporated2000
- Employees3.66k
- LocationOmnicell Inc4220 NORTH FREEWAYFORT WORTH 76137United StatesUSA
- Phone+1 (650) 251-6100
- Fax+1 (650) 251-6266
- Websitehttps://www.omnicell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alphatec Holdings Inc | 572.74m | -177.87m | 1.45bn | 839.00 | -- | -- | -- | 2.53 | -1.27 | -1.27 | 4.08 | 0.1546 | 0.8089 | 1.11 | 7.73 | 682,644.80 | -25.12 | -30.97 | -32.00 | -39.47 | 69.47 | 66.02 | -31.06 | -46.22 | 1.15 | -3.66 | 0.9596 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| 10X Genomics Inc | 629.74m | -182.55m | 1.61bn | 1.26k | -- | 2.23 | -- | 2.55 | -1.53 | -1.53 | 5.26 | 5.97 | 0.6677 | 2.40 | 6.72 | 500,193.00 | -19.36 | -25.52 | -21.99 | -29.05 | 66.63 | 75.88 | -28.99 | -48.53 | 4.12 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| AtriCure Inc | 447.57m | -38.92m | 1.74bn | 1.20k | -- | 3.74 | -- | 3.89 | -0.8322 | -0.8322 | 9.56 | 9.54 | 0.7365 | 1.63 | 8.41 | 372,977.50 | -6.40 | -3.72 | -7.35 | -4.10 | 74.79 | 74.36 | -8.70 | -7.64 | 2.59 | -13.76 | 0.1194 | -- | 20.84 | 14.64 | 34.49 | -- | 46.56 | -- |
| Integra Lifesciences Holdings Corp | 1.56bn | -6.54m | 1.77bn | 3.95k | -- | 1.17 | 13.89 | 1.13 | -0.0881 | -0.0881 | 20.22 | 19.73 | 0.401 | 1.59 | 5.99 | 396,583.90 | -0.1677 | 3.33 | -0.2002 | 3.68 | 59.29 | 63.67 | -0.4182 | 7.99 | 0.7261 | 4.05 | 0.5428 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
| Patterson Companies, Inc. | 6.53bn | 168.41m | 1.79bn | 7.60k | 11.08 | 1.88 | 6.93 | 0.2736 | 1.83 | 1.83 | 71.22 | 10.80 | 2.27 | 5.86 | 15.35 | 859,640.70 | 5.84 | 1.13 | 10.15 | 1.81 | 21.03 | 20.98 | 2.57 | 0.5157 | 0.6723 | 7.91 | 0.4474 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
| Rxsight Inc | 128.29m | -30.69m | 1.82bn | 374.00 | -- | 6.54 | -- | 14.15 | -0.8194 | -0.8194 | 3.40 | 6.89 | 0.5212 | 1.99 | 6.32 | 343,029.40 | -12.47 | -- | -13.62 | -- | 68.44 | -- | -23.92 | -- | 11.71 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Novocure Ltd | 577.74m | -149.78m | 1.85bn | 1.45k | -- | 5.12 | -- | 3.20 | -1.39 | -1.39 | 5.37 | 3.34 | 0.4879 | 3.59 | 8.74 | 397,617.30 | -12.65 | -7.74 | -20.29 | -8.95 | 76.42 | 77.22 | -25.93 | -14.69 | 1.44 | -- | 0.6446 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Tandem Diabetes Care Inc | 854.35m | -126.78m | 2.02bn | 2.40k | -- | 8.49 | -- | 2.36 | -1.94 | -1.94 | 13.08 | 3.62 | 0.9004 | 2.90 | 8.23 | 355,979.60 | -13.36 | -10.08 | -17.47 | -12.23 | 49.79 | 51.77 | -14.84 | -11.59 | 2.32 | -- | 0.5945 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Omnicell Inc | 1.06bn | -17.69m | 2.03bn | 3.66k | -- | 1.66 | 30.57 | 1.91 | -0.3917 | -0.3917 | 23.17 | 26.59 | 0.4704 | 5.90 | 4.06 | 291,563.30 | -0.7817 | 1.73 | -1.11 | 2.25 | 41.44 | 46.69 | -1.66 | 2.92 | 0.9529 | -- | 0.3172 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Premier Inc | 1.28bn | 147.17m | 2.15bn | 2.90k | 16.23 | 1.12 | 8.21 | 1.69 | 1.38 | 1.37 | 11.65 | 19.98 | 0.3562 | -- | 2.99 | 439,914.10 | 3.83 | 7.08 | 4.78 | 8.95 | 67.24 | 61.29 | 10.76 | 16.05 | -- | -- | 0.2771 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| Conmed Corp | 1.29bn | 131.74m | 2.22bn | 4.00k | 16.96 | 2.37 | 10.88 | 1.72 | 4.23 | 4.23 | 41.38 | 30.21 | 0.555 | 1.71 | 5.58 | 322,029.00 | 5.68 | 0.8972 | 6.62 | 1.02 | 55.65 | 54.95 | 10.23 | 1.65 | 1.06 | 5.22 | 0.5021 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Irhythm Technologies Inc | 560.03m | -150.66m | 2.31bn | 2.00k | -- | 32.22 | -- | 4.13 | -4.85 | -4.85 | 18.04 | 2.29 | 0.83 | 12.56 | 8.79 | 280,012.50 | -22.33 | -21.92 | -26.27 | -26.77 | 67.83 | 69.39 | -26.90 | -25.75 | 6.12 | -24.18 | 0.90 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| UFP Technologies Inc | 461.85m | 54.21m | 2.34bn | 3.09k | 43.55 | 7.11 | 34.79 | 5.06 | 7.00 | 7.00 | 59.64 | 42.89 | 0.8896 | 4.18 | 6.15 | 149,320.40 | 10.44 | 9.69 | 12.00 | 10.95 | 28.31 | 26.33 | 11.74 | 10.14 | 1.43 | 13.44 | 0.3919 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| LeMaitre Vascular Inc | 213.03m | 41.32m | 2.38bn | 614.00 | 58.07 | 7.19 | 46.72 | 11.17 | 1.82 | 1.82 | 9.41 | 14.73 | 0.5992 | 1.11 | 7.59 | 346,952.80 | 11.62 | 9.02 | 12.66 | 9.93 | 68.34 | 65.83 | 19.40 | 15.45 | 5.52 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Quidelortho Corp | 2.82bn | -1.87bn | 2.55bn | 7.10k | -- | 0.799 | -- | 0.9044 | -27.89 | -27.89 | 42.04 | 47.42 | 0.3674 | 2.62 | 7.84 | 396,859.20 | -24.34 | 11.34 | -27.75 | 12.91 | 47.62 | 62.71 | -66.25 | 20.93 | 0.8134 | 0.7419 | 0.4446 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| Enovis Corp | 2.00bn | -121.38m | 2.58bn | 6.55k | -- | 0.7745 | 17.63 | 1.29 | -2.21 | -2.17 | 36.43 | 59.61 | 0.4023 | 1.59 | 5.91 | 305,598.20 | -2.43 | -0.3569 | -2.66 | -0.41 | 56.96 | 48.19 | -6.03 | -1.06 | 1.12 | 0.9889 | 0.2876 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
Data as of Nov 21 2024. Currency figures normalised to Omnicell Inc's reporting currency: US Dollar USD
50.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.14m | 15.53% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.45m | 11.86% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.27m | 4.93% |
| Champlain Investment Partners LLCas of 30 Sep 2024 | 1.55m | 3.36% |
| Pacer Advisors, Inc.as of 30 Sep 2024 | 1.25m | 2.71% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 1.17m | 2.54% |
| Victory Capital Management, Inc. (Investment Management)as of 30 Sep 2024 | 1.15m | 2.50% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2024 | 1.14m | 2.48% |
| Macquarie Investment Management Business Trustas of 30 Sep 2024 | 1.12m | 2.43% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.10m | 2.40% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
